Hypertension

Alembic Pharmaceuticals gets USFDA nod for hypertension treatment capsules

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of hypertension. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules of strengths 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, Alembic Pharmaceuticals Ltd (Alembic) said in a statement. These capsules are indicated for the treatment of hypertension. These capsules may be used alone or in combination with other antihypertensive medications. Moreover, Diltiazem Hydrochloride is also indicated for the management of chronic stable angina and angina due to coronary artery spasm, the company said. Diltiazem Hydrochloride extended-release capsules 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of USD 105.3 million for the 12 months ended June 2024, the company ...

World Hypertension Day 2024: History, significance, theme, date and more

World Hypertension Day 2024: This day is celebrated every year to raise awareness about the risk of hypertension and its preventive measures. Here's all you need to know about this day

Omron's India arm, AliveCor to market AI-based portable ECG in India

While stroke risk is 3.4 times higher with hypertension, it becomes nearly five times higher with Afib, which means that people who frequently experience Afib could face a stroke shortly

Prefer deductible to co-pay in senior citizen health insurance cover

Last week Tata AIG General Insurance launched a plan for this group, adding to the considerable number of plans already available

Over 11.4% Indians diabetic, 35.5% suffer from hypertension: Lancet journal

The prevalence of diabetes in India is 11.4 per cent, while 35.5 per cent of people suffer from hypertension, according to the findings of a nationwide survey published in The Lancet Diabetes & Endocrinology journal. The study, conducted by the Madras Diabetes Research Foundation in collaboration with the Indian Council of Medical Research (ICMR) and other institutes, also found that the prevalence of generalised obesity and abdominal obesity in India stood at 28.6 and 39.5 per cent, respectively. The results, assessing the burden of non-communicable diseases (NCD) across the states, are based on a survey of 1,13,043 (over 1.1akh) people (33,537 urban and 79,506 rural residents), in 31 states and Union Territories in the country, between 2008 and 2020. The survey also showed that 35.5 per cent of Indians suffer from hypertension, 15.3 per cent of people have pre-diabetes, while an alarming 81.2 per cent have dyslipidaemia -- the imbalance of lipids such as cholesterol, low-density

World Hypertension Day 2023: History, significance, theme and more

World hypertension day is observed on May 17 every year. Read more about its history, theme and exercises to combat high blood pressure

Talking over mobile for over 30 minutes linked to developing hypertension

Researchers have found talking on a mobile phone for 30 minutes or longer per week to be linked with a 12 per cent increased risk of developing high blood pressure or hypertension. Almost three-quarters of the global population aged 10 and over own a mobile phone. Mobile phones emit low levels of radiofrequency energy, which has been linked with rises in blood pressure after short-term exposure, the study said. Hypertension is a major risk factor for heart attack and stroke and a leading cause of premature death globally. "It's the number of minutes people spend talking on a mobile that matter for heart health, with more minutes meaning greater risk," said study author Xianhui Qin of Southern Medical University, Guangzhou, China. "Years of use or employing a hands-free set-up had no influence on the likelihood of developing high blood pressure. More studies are needed to confirm the findings," said Qin. The study is published in the European Heart Journal - Digital Health. Using

India needs a new healthcare model to effectively manage hypertension

Success will help in reducing government spending for the poor battling the cost of treating non-communicable diseases

India lacks adequate community level data for hypertension control: Lancet

More than 50 per cent of patients in India are unaware of their high blood pressure, finds a study published in Lancet Regional Health Journal

Zydus Lifesciences gets USFDA's nod for generic hypertension drug

Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market blood pressure lowering drug Bisoprolol Fumarate and Hydrochlorothiazide tablets in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market the generic medication in multiple strengths, the Ahmedabad-based drug maker said in a statement. Bisoprolol Fumarate and hydrochlorothiazide combination is indicated to treat high blood pressure (hypertension). The drug will be manufactured at the company's formulation manufacturing facility at Ahmedabad SEZ, the company said. As per IQVIA MAT September 2022 data, Bisoprolol Fumarate and Hydrochlorothiazide tablets had annual sales of USD 27.1 million in the United States.

No heart issue despite hypertension in patients with short fingers: Study

Researchers in Berlin have spent decades on a peculiar hereditary illness that results in extraordinarily short fingers and incredibly high blood pressure in half of the members of specific families

Most people experience cardiac arrest early in morning, say experts

Doctors have often attributed a cardiac arrest to factors like diabetes, hypertension, smoking and alcohol intake, along with erratic lifestyle and lack of sleep

World Hypertension Day 2022: Dr Naresh Trehan gives tips on dealing with BP

World Hypertension Day 2022: Dr Naresh Trehan, CMD of Medanta, speaks to Business Standard on the spike in hypertension cases in India, the early signs, how to deal with the ailment

Unichem Laboratories gets USFDA approval for generic Nebivolol tablets

Unichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic version of Nebivolol tablets indicated for the treatment of hypertension

Alembic gets USFDA nod for generic hypertension treatment drug

Alembic said it has so far received 15 product approvals this year

India's health report card before Covid-19 pandemic: explained in 6 charts

Food poisoning and diarrhea were the main disease outbreaks in India before the Covid-19 pandemic hit. A look at India's health profile in 2019 through six charts

India needs to do more on hypertension, says Lancet global survey

Marginal increase in the number of people living with the ailment but diagnosis, treatment and control still need to catch up with best practices

Covid vaccination voluntary, those already infected can also get the jab

A detailed FAQ released by health ministry has also addressed issues on suitability in co-morbid cases, delivery procedure among other things

Pollution, hypertension among top 5 risk factors for death in India in 2019

Air pollution, hypertension, tobacco use, poor diet and high blood sugar levels were the top-five risk factors for death in India in 2019 according to a new study

OMRON India enters telemedicine segment via partnership with PhableCare

Healthcare monitoring equipment maker OMRON Healthcare India will provide remote hypertension management services at home